{"id":"bacillus-licheniformis","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal symptoms (abdominal discomfort, diarrhea, nausea)"},{"rate":null,"effect":"Fever or systemic inflammatory response"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bacillus licheniformis is a spore-forming bacterium used as a live biotherapeutic agent that colonizes the gastrointestinal tract and produces metabolites that support beneficial microbiota composition and intestinal barrier function. It may enhance immune tolerance and reduce pathogenic bacterial overgrowth through competitive exclusion and production of antimicrobial compounds. The mechanism leverages the microbiota-immune axis to restore dysbiosis-associated conditions.","oneSentence":"Bacillus licheniformis is a probiotic bacterium that modulates the gut microbiome and immune system to promote health and treat disease.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:35.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clostridium difficile infection (CDI) or recurrent CDI"},{"name":"Inflammatory bowel disease or microbiota dysbiosis-related conditions"}]},"trialDetails":[{"nctId":"NCT06710574","phase":"PHASE4","title":"Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2022-09-01","conditions":"Parkinson Disease, Movement Disorders, Rapid Eye Movement Sleep Behavior Disorder","enrollment":120},{"nctId":"NCT03978949","phase":"PHASE3","title":"Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP)","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2019-06-01","conditions":"Radiotherapy, Toxicity, Diarrhea","enrollment":248},{"nctId":"NCT03600974","phase":"","title":"A New System for GERD Diagnosis and Treatment","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2019-02-01","conditions":"GERD","enrollment":200},{"nctId":"NCT02993419","phase":"PHASE4","title":"Bacillus Particles Prevent Children Antibiotics Associated Diarrhea","status":"UNKNOWN","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","startDate":"2016-12","conditions":"Antibiotic-associated Diarrhea","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3712,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Biscanen cap."],"phase":"phase_3","status":"active","brandName":"Bacillus Licheniformis","genericName":"Bacillus Licheniformis","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bacillus licheniformis is a probiotic bacterium that modulates the gut microbiome and immune system to promote health and treat disease. Used for Clostridium difficile infection (CDI) or recurrent CDI, Inflammatory bowel disease or microbiota dysbiosis-related conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}